ライフサイエンスコーパス: cervical cancer

1 to influence the likelihood of conversion to cervical cancer.

2 al hysterectomy in patients with early stage cervical cancer.

3 mavirus (HPV) infections cause most cases of cervical cancer.

4 cervical intraepithelial neoplasia (CIN), or cervical cancer.

5 h HIV have a significantly increased risk of cervical cancer.

6 incidence rates (ASIRs) of HIV-attributable cervical cancer.

7 squamous intraepithelial lesions (HSIL) and cervical cancer.

8 ict the future incidence rates and burden of cervical cancer.

9 anti-cancerous properties of ormeloxifene in cervical cancer.

10 neoplasias (CINs) need be treated to prevent cervical cancer.

11 women, who are at a known, increased risk of cervical cancer.

12 1 months to not reached) among patients with cervical cancer.

13 umour activity against recurrent or advanced cervical cancer.

14 gy and Obstetrics staging system for uterine cervical cancer.

15 reatment, cure and prevention of HPV related cervical cancer.

16 PV) is a prerequisite for the development of cervical cancer.

17 her oncogenic types, the causative agents of cervical cancer.

18 ninvasive methods for the early detection of cervical cancer.

19 igh-risk human papillomavirus (hrHPV) causes cervical cancer.

20 linical trial of the secondary prevention of cervical cancer.

21 es (HPVs) are implicated in the aetiology of cervical cancer.

22 lated PAX1 associated with poor prognosis in cervical cancer.

23 ressor genes, is an important risk factor in cervical cancer.

24 extremely rare and aggressive neuroendocrine cervical cancer.

25 ts from the cohort of patients with advanced cervical cancer.

26 lity of antiangiogenesis therapy in advanced cervical cancer.

27 port of having ever had a screening test for cervical cancer.

28 (HPV) screening will be the primary test for cervical cancer.

29 including human papillomavirus (HPV)-caused cervical cancer.

30 preservation of women treated surgically for cervical cancer.

31 l hysterectomy for patients with early stage cervical cancer.

32 ng the association between HIV infection and cervical cancer.

33 of hypoxia levels in patients with tumors of cervical cancer.

34 d cancer registries to estimate incidence of cervical cancer.

35 omaviruses (HPV) are the causative agents of cervical cancer.

36 t a novel therapeutic target for HPV-induced cervical cancer.

37 However, not all infected women develop cervical cancer.

38 and treatment for pre-invasive and invasive cervical cancer.

39 NCT02285192) in 23 patients with uterine or cervical cancer.

40 ting dysregulation of these two microRNAs in cervical cancer.

41 women aged 20-29 years who were screened for cervical cancer.

42 forms of HPV16, the cause of the majority of cervical cancers.

43 were breast (33.3%), urothelial (12.5%), and cervical cancer (10.4%).Grade 3 adverse events were cons

44 Out of 147 primary cervical cancers, 113 were squamous cell carcinomas (SCC

45 east cancer, 10.2 (8.0-12.4) in survivors of cervical cancer, 18.9 (16.6-21.1) in survivors of testic

46 st cancer, 15.8% (14.8-16.7) in survivors of cervical cancer, 20.2% (18.9-21.5) in survivors of testi

47 on for recurrent sarcoma or locally advanced cervical cancer (3.3% each).

48 (634.7 per 100 000 person-years) followed by cervical cancer (36.6).

49 We estimate global cervical cancer 5-year net survival as 42.1% (95% uncert

50 cancer survival, we estimated stage-specific cervical cancer 5-year net survival in 200 countries and

51 y of care could substantially improve global cervical cancer 5-year net survival, with quality of car

52 Our model projected that among all cervical cancers, 50% and 75% of women acquired their ca

53 rica, 63.8% (95% CI 58.9-68.1) of women with cervical cancer (9200 new cases, 95% CI 8500-9800) were

54 ncluding self-sampling-has potential to make cervical cancer a rare disease in the decades to come.

55 f human papillomavirus-associated metastatic cervical cancer after tumor-infiltrating adoptive T cell

56 We estimated the pooled risk of cervical cancer among women living with HIV across four

57 are needed for HSIL to reduce the burden of cervical cancer among women living with HIV.

58 evalence in abnormal cytology (from ASCUS to cervical cancer) among Mexican women which were undergoi

59 distant metastasis was 13.7% (21 of 153) for cervical cancer and 11.8% (24 of 203) for endometrial ca

60 e rates were 26.3% (95% CI, 9.1 to 51.2) for cervical cancer and 20.0% (95% CI, 0.5 to 71.6) for vagi

61 Approximately 570 000 cases of cervical cancer and 311 000 deaths from the disease occu

62 k stratification of women when screening for cervical cancer and inform HPV vaccination strategies.

63 her odds of pancreatic, kidney, uterine, and cervical cancer and lower odds of esophageal cancer and

64 Benefits increased with advanced stage of cervical cancer and more efficient scale up of radiother

65 elial neoplasia of grade 2 or 3 and cases of cervical cancer and noncervical HPV-associated cancer by

66 elial neoplasia of grade 2 or 3 and cases of cervical cancer and noncervical HPV-associated cancer by

67 est for gliomas and sarcomas and highest for cervical cancer and oropharyngeal head and neck cancer.

68 In Africa, cervical cancer and placental malaria (PM) are a major p

69 on of women living with HIV among women with cervical cancer and population attributable fractions an

70 hat wider implementation will help to reduce cervical cancer and precursors incidence.

71 than half a million women are diagnosed with cervical cancer and the disease results in over 300 000

72 el the dynamics of cell cycle in HeLa (human cervical cancer) and S. cerevisiae cells.

73 l immunisation, and screening for breast and cervical cancers) and four treatment indicators (skilled

74 a 2+ [CIN2+]) is an effective way to prevent cervical cancer, and recommendations exist for the monit

75 ccination coverage, changes in screening for cervical cancer, and risk behaviors for acquiring HPV.

76 or advanced HPV-positive (HPV-16 or HPV-18) cervical cancer, and who had progressed after available

77 cination and the subsequent risk of invasive cervical cancer are lacking.

78 Breast and cervical cancer are major threats to the health of women

79 omes for patients with recurrent or advanced cervical cancer are poor.

80 Most cervical cancers are caused by vaccine-preventable infec

81 Breast and cervical cancers are the commonest cancers diagnosed in

82 study aimed to assess the existing burden of cervical cancer as a baseline from which to assess the e

83 hape and monitor the initiative to eliminate cervical cancer as a major public health problem.

84 ng, and treatment interventions to eliminate cervical cancer as a public health problem during the 21

85 loping a global strategy towards eliminating cervical cancer as a public health problem, which propos

86 nced a call to action for the elimination of cervical cancer as a public health problem.

87 al has issued a call for action to eliminate cervical cancer as a public health problem.

88 isk human papillomaviruses (HR-HPVs) promote cervical cancer as well as a subset of anogenital and he

89 2019 could reduce age-standardised rates of cervical cancer at ages 25-64 years by 19%, from 15.1 in

90 ith a substantially reduced risk of invasive cervical cancer at the population level.

91 nce were performed on 30 women with advanced cervical cancers at three time points (within 2 weeks be

92 with approximately 6.5% of women developing cervical cancer before age 75 years.

93 wanted to examine whether IPSA could improve cervical cancer brachytherapy plans giving D90 < 6 Gy (w

94 n living with HIV and to estimate the global cervical cancer burden associated with HIV.

95 However, the contribution of HIV to cervical cancer burden at a population level has not bee

96 d updates to demography, disability weights, cervical cancer burden estimates resulted in a 26% incre

97 obal Burden of Disease (GBD) 2017 study, and cervical cancer burden from the Global Cancer Incidence,

98 Africa, where a substantial HIV-attributable cervical cancer burden has added to the existing cervica

99 hods for demography, disability weights, and cervical cancer burden, and generated revised estimates

100 t low rates and were eclipsed by high KS and cervical cancer burden.

101 ical cancer burden has added to the existing cervical cancer burden.

102 Radiotherapy is standard of care for cervical cancer, but major global gaps in access exist,

103 We obtained relative risks (RRs) of cervical cancer by screening history (never screened, re

104 Although current methods of treatment for cervical cancer can ablate lesions, preventing metastati

105 We calculated the number of cervical cancer cases and deaths in a given country, dir

106 nt thresholds, and to estimate the number of cervical cancer cases averted on the path to elimination

107 tion and screening coverage on the number of cervical cancer cases averted over the 50 years from 202

108 e potential to avert up to 12.5-13.4 million cervical cancer cases by 2069, and could achieve average

109 er intervention, there would be 44.4 million cervical cancer cases diagnosed globally over the period

110 Globally, 5.8% (95% CI 4.6-7.3) of new cervical cancer cases in 2018 (33 000 new cases, 95% CI

111 Health impact was presented in terms of cervical cancer cases, deaths, or disability-adjusted li

112 Cervical cancer (CC) remains highest in the mortality of

113 to prevent 1 anogential warts (AGW) case or cervical cancer (CC) was similar for routine + catch-up

114 16 (HPV16) is the primary causative agent of cervical cancer (CC).

115 l line (Human Dermal Fibroblasts, HDF) and a cervical cancer cell line (HeLa), as a function of time

116 te of irinotecan (SN-38), on Trop-2 positive cervical cancer cell lines and a xenograft model.

117 r loss of expression of the two microRNAs in cervical cancer cell lines and primary tumors, indicatin

118 cidates its possible mechanisms of action on cervical cancer cell lines CaSki and HeLa positive for H

119 1 was found overexpressed in HPV-16 positive cervical cancer cell lines in an HPV-16 E6-dependent man

120 hsa-miR-34a or hsa-miR-449a in HeLa and SiHa cervical cancer cell lines resulted in DNA damage respon

121 n and, in contrast to all other HPV-positive cervical cancer cell lines, they harbored a gain-of-func

122 issues, including normal and tumor lung, and cervical cancer cell lines.

123 xenograft in vivo in nude mice, and suppress cervical cancer cell migration and invasion.

124 of human cervical cancer cells in vitro and cervical cancer cell xenograft in vivo in nude mice, and

125 Cervical cancer cell-derived IL6 directly suppressed IL1

126 ormeloxifene induces radio-sensitization in cervical cancer cells and caused potent tumor growth inh

127 next-generation sequencing (NGS) analysis of cervical cancer cells and their EVs compared with cervic

128 sing MKN-45 gastric or FOLR1-expressing HeLa cervical cancer cells confirmed noninterference of the a

129 We previously demonstrated that cervical cancer cells contribute to Th17 cell recruitmen

130 Cervical cancer cells differentially regulate IL23 and I

131 nergistically to inhibit the growth of human cervical cancer cells in vitro and cervical cancer cell

132 ted tumorigenic and metastatic properties of cervical cancer cells via arresting cell cycle at G1-S t

133 In cervical cancer cells, human papilloma virus (HPV) prote

134 y-directed recombination in E6/E7-expressing cervical cancer cells.

135 RISPR/Cas9), the SIRT1 gene was removed from cervical cancer cells.

136 TRL-positive cancer bearing G-CSF expressing cervical cancer cells.

137 uorescent cation, Hoechst 33258 (H33258), in cervical cancer cells.

138 s, with male circumcision protecting against cervical cancer, cervical dysplasia, herpes simplex viru

139 EM using DNA tiling data on an institutional cervical cancer cohort (96.5% accuracy).

140 Cervical cancer continues to be a major public health pr

141 unded via the NHMRC Centre of Excellence for Cervical Cancer Control (C4; APP1135172).

142 a point-of-care test and treat programme for cervical cancer control in Papua New Guinea, improving t

143 Effective cervical cancer control requires a comprehensive strateg

144 Australia, Centre for Research Excellence in Cervical Cancer Control, Canadian Institute of Health Re

145 Australia Centre for Research Excellence in Cervical Cancer Control.

146 een HPV vaccination and the risk of invasive cervical cancer, controlling for age at follow-up, calen

147 en benchmarked using cell line data and TCGA cervical cancer data.

148 umans study of PLG in women with uterine and cervical cancer demonstrates its feasibility and its abi

149 o streptococcal infection (9.4 million), and cervical cancer due to HPV (8.0 million).

150 ncluding 4,245 patients with newly diagnosed cervical cancer during 2002-2011 in Sweden.

151 an papillomaviruses (HPV) cause over 500 000 cervical cancers each year, most of which occur in low-r

152 present study aimed to investigate the anti-cervical cancer effects of metformin, a first-line thera

153 PV vaccination coverage of girls can lead to cervical cancer elimination in most LMICs by the end of

154 The WHO Cervical Cancer Elimination Modelling Consortium (CCEMC)

155 The WHO Cervical Cancer Elimination Modelling Consortium (CCEMC)

156 n regions in which all countries can achieve cervical cancer elimination with girls-only vaccination,

157 A draft global strategy to accelerate cervical cancer elimination, with goals and targets for

158 velopment of the final goals and targets for cervical cancer elimination.

159 vical specimens from the Study to Understand Cervical Cancer Endpoints and Early Determinants (SUCCEE

160 pelvic examination for conditions other than cervical cancer, gonorrhea, and chlamydia, for which the

161 r any gynecologic cancer or condition except cervical cancer, gonorrhea, and chlamydia, which are cov

162 mavirus (HPV) infection is the main cause of cervical cancer has resulted in the development of proph

163 that dispose certain individuals to develop cervical cancer has the potential to enable the developm

164 any malignancies, including locally advanced cervical cancer, head and neck cancer, and lung cancer.

165 tify proteins interacting with TCTP in human cervical cancer HeLa cells.

166 discovery: human embryonic kidney (HEK293), cervical cancer (HeLa), and liver cancer (HepG2).

167 beta-estradiol induces CINs that progress to cervical cancer if the treatment is continued.

168 eductions and will be necessary to eliminate cervical cancer in countries with the highest burden.

169 In the next 25 years, the epidemiology of cervical cancer in England, UK, will change: human papil

170 logy, with a prevalence of 44% [101/228] for cervical cancer in HIV-negative women (PR vs normal cyto

171 tion in the rate of premature mortality from cervical cancer in LMICs is possible, contributing to th

172 We estimated age-specific absolute risks of cervical cancer in the absence of screening (derived fro

173 than 44 million women will be diagnosed with cervical cancer in the next 50 years if primary and seco

174 rnal-beam radiotherapy and brachytherapy for cervical cancer in upper-middle-income, lower-middle-inc

175 omavirus 58 (HPV58) is found in 10 to 18% of cervical cancers in East Asia but is rather uncommon els

176 In high-income countries, cervical cancer incidence and mortality have more than h

177 ot yet been defined, but an absolute rate of cervical cancer incidence could be chosen for such a thr

178 2020 onwards would result in average annual cervical cancer incidence declining to less than six new

179 An elimination threshold in terms of cervical cancer incidence has not yet been defined, but

180 dicted to reduce the median age-standardised cervical cancer incidence in LMICs from 19.8 (range 19.4

181 cer cases by 2069, and could achieve average cervical cancer incidence of around four per 100 000 wom

182 ds examined were an average age-standardised cervical cancer incidence of four or fewer cases per 100

183 predefined criteria, projected reductions in cervical cancer incidence over time in 78 LMICs for thre

184 In this scenario, average cervical cancer incidence rates will decline to 0.8 case

185 ge, vaccination yielded a 22.9% reduction in cervical cancer incidence, with 38.4 million requiring e

186 ancer-specific mortality among patients with cervical cancer, independent of tumor characteristics an

187 standardised incidence and mortality rate of cervical cancer, indirectly standardised incidence ratio

188 wever, the significance of LKB1 mutations in cervical cancer initiation and progress has not been exa

189 Correspondingly, cervical cancer-instructed fibroblasts increased IL23 pr

190 Cocultures of cervical cancer-instructed mDCs and cervical fibroblasts

191 asts increased IL23 production in cocultured cervical cancer-instructed mDCs, which mediated subseque

192 ed expression of the IL12 subunit IL12p35 in cervical cancer-instructed mDCs.

193 Cervical cancer is among the most common preventable can

194 ir "causal" HPV infection that develops into cervical cancer is poorly understood and practically uno

195 ination, supporting the notion that invasive cervical cancer is preventable.

196 Cervical cancer is the fourth most common cancer among w

197 Cervical cancer is the fourth most common cancer in wome

198 Human cervical cancer is the fourth most common carcinoma in w

199 Cervical cancer is the most common cancer affecting sub-

200 0.71]; I(2)=97.58% and no publication bias), cervical cancer (k=23; 0.89 [0.84-0.95]; I(2)=98.47% and

201 lness, 1 023 288 in the general population), cervical cancer (k=29; 295 688 with mental illness, 3 54

202 ication among patients with locally advanced cervical cancer (LACC) and paraaortic lymph node (PALN)

203 treatment of patients with locally advanced cervical cancer (LACC), 40% of patients present with dis

204 f hsa-miR-34a and hsa-miR-449a expression in cervical cancer leads to overexpression of PACS-1 and su

205 We discuss the role of imaging in cervical cancer management and estimate the potential su

206 for their anticancer activity against HeLa (cervical cancer), MCF-7 (breast cancer), HL-60 (Human pr

207 n of the Th17-promoting cytokine IL23 in the cervical cancer micromilieu and found CD83(+) mature den

208 , our study defines a mechanism by which the cervical cancer micromilieu supports IL23-mediated Th17

209 the 90-70-90 triple-intervention targets on cervical cancer mortality and deaths averted over the ne

210 of the WHO elimination strategy would reduce cervical cancer mortality by almost 99% and save more th

211 Reductions in age-standardised rates of cervical cancer mortality in 78 low-income and lower-mid

212 In 2020, the estimated cervical cancer mortality rate across all 78 LMICs was 1

213 ccination alone would have minimal impact on cervical cancer mortality, leading to a 0.1% (0.1-0.5) r

214 For estimation of cervical cancer mortality, we used the WHO mortality dat

215 fective cancer treatment is needed to reduce cervical cancer mortality.

216 Approximately 90% of cervical cancers occur in low-income and middle-income c

217 HPVs), and persistent HPV infections lead to cervical cancer or other deadly cancers.

218 age, she had had only sporadic screening for cervical cancer over the past 15 years.

219 cal cancer cells and their EVs compared with cervical cancer patient plasma EV-derived small RNAs, we

220 96%) to in vivo circulating EVs derived from cervical cancer patient plasma.

221 represent a novel targeted therapy option in cervical cancer patients overexpressing Trop-2.

222 utcomes and circulating neutrophil counts in cervical cancer patients treated with definitive chemora

223 rotein mixtures extracted from the tissue of cervical cancer patients was also utilized to validate t

224 programmed death ligand 1-positive advanced cervical cancer, pembrolizumab demonstrated antitumor ac

225 ess around the time of diagnosis of invasive cervical cancer places patients at a higher risk of canc

226 regional collaborative approaches, enhancing cervical cancer prevention, improving cancer surveillanc

227 e impact of potential scale-up scenarios for cervical cancer prevention, in order to predict the futu

228 assays based on nfGNPs for HPV detection and cervical cancer prevention.

229 Clearance of surgical margins in cervical cancer prevents the need for adjuvant chemoradi

230 Cervical cancer ranked in the top three cancers affectin

231 2070 to identify the earliest years by which cervical cancer rates could drop below two absolute leve

232 nced tumor stage, lymph node metastasis, and cervical cancer recurrence.

233 gement in HIV clinics, especially for KS and cervical cancer, remain important priorities in the curr

234 n screening and development of HPV vaccines, cervical cancer remains one of the deadliest malignancie

235 We aimed to investigate cervical cancer risk among women living with HIV and to

236 gration of HPV16, and somatic mutation in 96 cervical cancer samples from Guatemala.

237 study of in situ (CIS) and invasive squamous cervical cancer (SCC).

238 of 1848 Slovenian women attended 2 rounds of cervical cancer screening 3 years apart and provided dat

239 in the self-reported lifetime prevalence of cervical cancer screening among countries within regions

240 s time period, and more modest reductions in cervical cancer screening and sexual risk behaviors.

241 idered when clinical practice guidelines for cervical cancer screening are reassessed.

242 sting may be a promising approach to improve cervical cancer screening coverage, especially among wom

243 From 2008-2015, both CIN2+ rates and cervical cancer screening declined in women aged 18-24 y

244 Cervical cancer screening efforts should be increased, p

245 HPV vaccination and cervical cancer screening for women living with HIV are

246 gic exams are two of the biggest barriers to cervical cancer screening for women.

247 However, evidence on prevalence levels of cervical cancer screening in low- and middle-income coun

248 en and treat is the recommended approach for cervical cancer screening in low-resource settings, but

249 lomavirus (HPV) tests are needed for primary cervical cancer screening in lower-resource regions.

250 ong Mexican women which were undergoing from cervical cancer screening in the Salud Digna clinics in

251 Cervical cancer screening might contribute to the preven

252 tential use of DNA methylation detection, in cervical cancer screening or triage of mildly abnormal c

253 HPV-based cervical cancer screening programmes might help to strat

254 luating the effectiveness of vaccination and cervical cancer screening programs.

255 llomavirus (HPV) vaccine uptake and changing cervical cancer screening recommendations.

256 We aimed to investigate if routine cervical cancer screening results-namely high-risk human

257 tion of the cervix with acetic acid (VIA) as cervical cancer screening strategy in resource-poor sett

258 increase their surveillance and inclusion in cervical cancer screening triage.

259 For cervical cancer screening, we used the SurePath liquid-b

260 in the self-reported lifetime prevalence of cervical cancer screening.

261 ssing information for the survey question on cervical cancer screening.

262 tion (Cervex-Brush or Cytobrush/spatula) for cervical cancer screening.

263 r patients with pancreatic, renal, lung, and cervical cancers showed that high-level expression of MC

264 Despite efforts in prevention, cervical cancer still presents with a high worldwide inc

265 frequently among survivors of breast cancer, cervical cancer, testicular cancer, and Hodgkin lymphoma

266 survived at least 30 years from diagnosis of cervical cancer, testicular cancer, Hodgkin lymphoma in

267 sion, which was demonstrated to be higher in cervical cancer than the normal surrounding tissue.

268 xually transmitted infection associated with cervical cancer that frequently occurs as a coinfection

269 3H-AS1 was also found to be altered in human cervical cancer tissues and high expression of this lncR

270 f care could improve 5-year net survival for cervical cancer to 62.5% (57.7-67.8).

271 IV prevalence and GLOBOCAN 2018 estimates of cervical cancer to calculate the proportion of women liv

272 erties that are associated with HPV-positive cervical cancer transformed cells such as rapid growth a

273 will also be needed to successfully scale up cervical cancer treatment worldwide.

274 Methods: Patients with cervical cancer underwent baseline and repeat (18)F-FDG

275 udy period, we evaluated girls and women for cervical cancer until their 31st birthday.

276 The estimated age-standardised incidence of cervical cancer was 13.1 per 100 000 women globally and

277 The cumulative incidence of cervical cancer was 47 cases per 100,000 persons among w

278 Globally, the average age at diagnosis of cervical cancer was 53 years, ranging from 44 years (Van

279 The global average age at death from cervical cancer was 59 years, ranging from 45 years (Van

280 ol mice treated with 17beta-estradiol alone, cervical cancer was absent in the MPA-treated mice.

281 Cervical cancer was diagnosed in 19 women who had receiv

282 The pooled risk of cervical cancer was increased in women living with HIV (

283 umab for patients with recurrent or advanced cervical cancer was safe and treatment-related adverse e

284 Cervical cancer was the fourth most common cancer in wom

285 Cervical cancer was the leading cause of cancer-related

286 model that simulates the natural history of cervical cancer, we estimated the cumulative number of c

287 ASIRs of HIV-attributable cervical cancer were more than 20 per 100 000 in six cou

288 Mouse models of cervical cancer were used to evaluate the relationship b

289 n many forms of cancer, including breast and cervical cancers, were significantly increased during th

290 rogrammes have been successful for colon and cervical cancers, where subsequent surgical removal of p

291 ents an alternative therapeutic modality for cervical cancer which may have rapid clinical translatio

292 over time in HPV16 infections progressing to cervical cancer, which could influence risk stratificati

293 se was observed in a patient with metastatic cervical cancer who received 2.7 x 10(9) cells (ongoing

294 ients with recurrent or advanced, inoperable cervical cancer, who were aged 18 years or older with Ea

295 ancers, we describe the burden of breast and cervical cancer, with an emphasis on global and regional

296 for the treatment of recurrent or metastatic cervical cancer, with an overall response rate of 14.3%.

297 is developing a global strategy to eliminate cervical cancer, with goals for screening prevalence amo

298 a statistical analysis of existing trends in cervical cancer worldwide using high-quality cancer regi

299 HPV16 causes half of cervical cancers worldwide; for unknown reasons, most in

300 d we assumed that 50% of women with invasive cervical cancer would receive appropriate surgery, radio